Skip to main navigation

Back to SpringWorksTx.com
Investors & Media
Contact Us
Linkedin
Twitter

Overview
News & Events
- Press Releases
- Events & Presentations
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
Investors + Media
Medical Professionals
Contact Us
Linkedin
Twitter

Press Releases

Items Per Page

Year

12 Mar 2020

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

PDF Version

27 Feb 2020

MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

PDF Version

18 Feb 2020

SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

PDF Version

13 Jan 2020

Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

PDF Version

06 Jan 2020

SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

PDF Version

09 Dec 2019

Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH)

PDF Version

12 Nov 2019

SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

PDF Version

24 Oct 2019

SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)

PDF Version

24 Sep 2019

European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma

PDF Version

17 Sep 2019

SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares

PDF Version

Pagination

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Next page
Last page

Displaying 101 - 110 of 130

Springworks - Toolkits

Print Page
Email Alerts
RSS Feeds
Investor Contacts

Request E-mail Alerts

Social Links

Footer 1

Who We Are
Focus Areas

Footer 2

Pipeline
Careers
- View Opportunities

Footer 3

Patients
Contact

Footer 4

Investors & Media

© 2023 SpringWorks Therapeutics. All rights reserved.

Copyright Links

Privacy Policy
Terms of Use
Cookie Policy